読み込み中
PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
最新データ
￥318
−￥3.00 · -0.93%
日中の時刻はJSTです。市場データは遅延する場合があります。
PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
日中レンジ
現在 ￥318
52週レンジ
現在 ￥318
日中の時刻はJSTです。市場データは遅延する場合があります。
PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
日中レンジ
現在 ￥318
52週レンジ
現在 ￥318
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（JPY） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 15.66億 JPY | 15.41億 JPY | 17.15億 JPY | 21.24億 JPY | 13.25億 JPY |
| 売上原価 | 3.76億 JPY | 4.33億 JPY | 5.2億 JPY | 5.68億 JPY | 5.97億 JPY |
| 粗利益 | 11.89億 JPY | 11.08億 JPY | 11.95億 JPY | 15.56億 JPY | 7.28億 JPY |
| 研究開発 | 1.91億 JPY | 2.74億 JPY | 2.07億 JPY | 2.05億 JPY | 2.2億 JPY |
| 販売・一般管理 | 9.15億 JPY | 9.7億 JPY | 9.75億 JPY | 8.36億 JPY | 6.65億 JPY |
| 営業費用 | 11.06億 JPY | 12.43億 JPY | 11.84億 JPY | 10.48億 JPY | 8.95億 JPY |
| 受取利息 | 940.8万 JPY | 833.1万 JPY | 596.2万 JPY | 222.9万 JPY | 20.3万 JPY |
| 支払利息 | 479.8万 JPY | 524.6万 JPY | 292.7万 JPY | 307.2万 JPY | 95.2万 JPY |
| 減価償却費と償却費 | 3375万 JPY | 2819.6万 JPY | 2522.5万 JPY | 2370万 JPY | 8623.8万 JPY |
| 営業利益 | 8276.9万 JPY | −1.35億 JPY | 1106.3万 JPY | 5.08億 JPY | −1.68億 JPY |
| 純利益 | 1.25億 JPY | −4.46億 JPY | 2637.8万 JPY | 4.93億 JPY | −3.88億 JPY |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
